TEVA Latest Press Releases

-- October 27, 2026 --

Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline Globe Newswire 8:00 AM

-- October 20, 2026 --

UEG Week: Teva and Sanofi's Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn's Disease Globe Newswire 8:00 AM

-- October 12, 2026 --

Teva to Host R&D Day on Wednesday, November 11 in New York City Globe Newswire 5:45 PM

-- October 9, 2026 --

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia Globe Newswire 7:00 AM

-- October 2, 2026 --

Journal of Child Neurology Publishes Review Highlighting Dopamine's Role in Tourette Syndrome and Ecopipam's Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients Globe Newswire 8:00 AM

Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome Globe Newswire 8:00 AM

-- September 30, 2026 --

TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness Globe Newswire 4:32 PM

-- September 28, 2026 --

Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA (denosumab-adet), a Biosimilar to Xgeva (denosumab) Globe Newswire 4:00 PM

-- September 23, 2026 --

Teva Releases Q3 2026 Aide Memoire Globe Newswire 4:45 PM

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET Globe Newswire 4:45 PM

-- September 18, 2026 --

New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients Globe Newswire 4:32 PM

Teva Highlights New Real-World Data Showing UZEDY (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs Globe Newswire 4:31 PM

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults Globe Newswire 4:30 PM

-- September 16, 2026 --

Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care Globe Newswire 8:00 AM

-- September 14, 2026 --

Temporal Raises $550 Million in Series E Round: NYSE Content Update PRNewswire 9:05 AM

Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy Globe Newswire 8:03 AM

-- September 10, 2026 --

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes Globe Newswire 6:04 AM

-- September 7, 2026 --

Teva Announces Launch of Offering of Senior Notes Globe Newswire 3:53 AM

-- September 4, 2026 --

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline Globe Newswire 11:30 AM

-- September 2, 2026 --

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential Globe Newswire 7:03 AM

-- September 1, 2026 --

Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September Globe Newswire 4:30 PM

-- August 31, 2026 --

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S. Globe Newswire 4:06 PM

-- August 28, 2026 --

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy Globe Newswire 6:17 AM

-- August 19, 2026 --

U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome Globe Newswire 8:30 AM

-- August 11, 2026 --

Moody's Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy Globe Newswire 8:00 AM

-- July 29, 2026 --

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy Globe Newswire 7:00 AM

-- July 9, 2026 --

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus (ocrelizumab) for Multiple Sclerosis Business Wire 8:45 AM

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus (ocrelizumab) for Multiple Sclerosis Globe Newswire 8:30 AM

Teva and Samsung Bioepis Enter Commercialization Agreement for OPUVIZ, a Biosimilar Referencing Eylea (aflibercept), in Canada PRNewswire 8:05 AM

-- July 7, 2026 --

Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results Globe Newswire 7:00 AM

-- June 18, 2026 --

Teva Releases Q2 2026 Aide Memoire Globe Newswire 5:00 PM

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome Globe Newswire 4:56 PM

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET Globe Newswire 4:30 PM

-- June 10, 2026 --

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy Globe Newswire 12:03 PM

-- June 8, 2026 --

Teva's Data on AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care Globe Newswire 8:00 AM

-- June 5, 2026 --

Teva Presents New Data on AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea Globe Newswire 11:30 AM

-- June 4, 2026 --

Teva Expands European biosimilars portfolio with launch of AHZANTIVE (aflibercept) biosimilar to Eylea Globe Newswire 8:30 AM

-- June 1, 2026 --

Teva to Present at the Goldman Sachs Global Healthcare Conference Globe Newswire 4:30 PM